337 related articles for article (PubMed ID: 27696009)
1. Does drug price-regulation affect healthcare expenditures?
Ben-Aharon O; Shavit O; Magnezi R
Eur J Health Econ; 2017 Sep; 18(7):859-867. PubMed ID: 27696009
[TBL] [Abstract][Full Text] [Related]
2. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
[TBL] [Abstract][Full Text] [Related]
3. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
Davidova J; Praznovcova L; Lundborg CS
Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
[TBL] [Abstract][Full Text] [Related]
4. European healthcare policies for controlling drug expenditure.
Ess SM; Schneeweiss S; Szucs TD
Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
[TBL] [Abstract][Full Text] [Related]
5. Pricing and reimbursement of pharmaceuticals in Sweden.
Jönsson B
Pharmacoeconomics; 1994; 6 Suppl 1():51-60. PubMed ID: 10172482
[TBL] [Abstract][Full Text] [Related]
6. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
Aaserud M; Dahlgren AT; Kösters JP; Oxman AD; Ramsay C; Sturm H
Cochrane Database Syst Rev; 2006 Apr; (2):CD005979. PubMed ID: 16625648
[TBL] [Abstract][Full Text] [Related]
7. The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs.
Grootendorst PV; Marshall JK; Holbrook AM; Dolovich LR; O'Brien BJ; Levy AR
Health Serv Res; 2005 Oct; 40(5 Pt 1):1297-317. PubMed ID: 16174135
[TBL] [Abstract][Full Text] [Related]
8. Spending on medicines in Israel in an international context.
Sax P
Isr Med Assoc J; 2005 May; 7(5):286-91. PubMed ID: 15909459
[TBL] [Abstract][Full Text] [Related]
9. Cost containment interventions introduced on the community drugs schemes in Ireland-evaluation of expenditure trends using a national prescription claims database.
Usher C; Tilson L; Bennett K; Barry M
Clin Ther; 2012 Mar; 34(3):632-9. PubMed ID: 22381716
[TBL] [Abstract][Full Text] [Related]
10. The evolution of Taiwan's National Health Insurance drug reimbursement scheme.
Hsu JC; Lu CY
Daru; 2015 Feb; 23(1):15. PubMed ID: 25889754
[TBL] [Abstract][Full Text] [Related]
11. The 1996 pricing and reimbursement policy in The Netherlands.
de Vos CM
Pharmacoeconomics; 1996; 10 Suppl 2():75-80. PubMed ID: 10163439
[TBL] [Abstract][Full Text] [Related]
12. [Assessment of the pharmaceutical expenditure in Hungary].
Inotai A; Merész G; Kaló Z
Acta Pharm Hung; 2010; 80(4):162-72. PubMed ID: 21404477
[TBL] [Abstract][Full Text] [Related]
13. Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria.
Vassileva M; Kamusheva M; Manova M; Savova A; Tachkov K; Petrova G
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):733-742. PubMed ID: 30900482
[No Abstract] [Full Text] [Related]
14. Convergence of decision rules for value-based pricing of new innovative drugs.
Gandjour A
Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):209-13. PubMed ID: 25327543
[TBL] [Abstract][Full Text] [Related]
15. Price cuts and drug spending in South Korea: the case of antihyperlipidemic agents.
Kwon HY; Hong JM; Godman B; Yang BM
Health Policy; 2013 Oct; 112(3):217-26. PubMed ID: 24075008
[TBL] [Abstract][Full Text] [Related]
16. Pricing and reimbursement of orphan drugs: the need for more transparency.
Simoens S
Orphanet J Rare Dis; 2011 Jun; 6():42. PubMed ID: 21682893
[TBL] [Abstract][Full Text] [Related]
17. [Is the price of cancer drugs related to the cost of develo-pment and production or to the economic value of their clincal efficacy?].
Russi A; Serena M; Palozzo AC
Recenti Prog Med; 2016 Apr; 107(4):181-5. PubMed ID: 27093327
[TBL] [Abstract][Full Text] [Related]
18. Pricing and reimbursement of pharmaceuticals in Belgium.
Annemans L; Crott R; De Clercq H; Huybrechts M; Peys F; Robays H; Steens I; Vanschoubroek K; Winderickx P
Pharmacoeconomics; 1997 Mar; 11(3):203-9. PubMed ID: 10165309
[TBL] [Abstract][Full Text] [Related]
19. Drug Policy in Romania.
Radu CP; Pana BC; Furtunescu FL
Value Health Reg Issues; 2018 Sep; 16():28-32. PubMed ID: 29704726
[TBL] [Abstract][Full Text] [Related]
20. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes.
Ioannides-Demos LL; Ibrahim JE; McNeil JJ
Pharmacoeconomics; 2002; 20(9):577-91. PubMed ID: 12141886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
